跳轉至內容
Merck
全部照片(1)

Key Documents

更多文件

1461003

USP

尼亚生

United States Pharmacopeia (USP) Reference Standard

同義詞:

烟酸, 3-吡啶甲酸, 吡啶-3-羧酸, 尼亚生, 抗糙皮病因子, 维生素 B3

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C6H5NO2
CAS號碼:
59-67-6
分子量：:
123.11
Beilstein:
109591
MDL號碼:
MFCD00006391
分類程式碼代碼:
41116107
PubChem物質ID:
329750552
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

nicotinic acid

製造商／商標名

USP

技術

HPLC: suitable

mp

236-239 °C (lit.)

溶解度

ethanol: 12.5 g/L at 25 °C
water: soluble 180 g/L at 20 °C

密度

1.473 g/cm3 at 25 °C

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

OC(=O)c1cccnc1

InChI

1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)

InChI 密鑰

PVNIIMVLHYAWGP-UHFFFAOYSA-N

尋找類似的產品？ 前往 產品比較指南

相關類別

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Niacin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Niacin Tablets
  • Niacin Injection
  • Niacin Extended-Release Tablets
  • Inositol Niacinate
  • Niacinamide
  • Water-Soluble Vitamins Capsules

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

象形圖

Exclamation mark
GHS07

訊號詞

Warning

危險聲明

H319

危險分類

Eye Irrit. 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 1

閃點（°F）

379.4 °F - closed cup

閃點（°C）

193 °C - closed cup

分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Slide 1 of 4

1 of 4

Nicotinic Acid A component of coenzymes NAD+ and NADP+.

Millipore

481918

Nicotinic Acid

核黄素 United States Pharmacopeia (USP) Reference Standard

USP

1603006

核黄素

设备鉴定用烟酸 European Pharmacopoeia (EP) Reference Standard

Y0001995

设备鉴定用烟酸

烟酸 for synthesis

Sigma-Aldrich

8.18714

烟酸

Vaijinath S Kamanna et al.
Current opinion in lipidology, 24(3), 239-245 (2013-04-27)
This review focuses on the current understanding of the physiological mechanisms of action of niacin on lipid metabolism and atherosclerosis. Emerging findings indicate that niacin decreases hepatic triglyceride synthesis and subsequent VLDL/LDL secretion by directly and noncompetitively inhibiting hepatocyte diacylglycerol
James B Kirkland
Mutation research, 733(1-2), 14-20 (2011-12-06)
Through its involvement in over 400 NAD(P)-dependent reactions, niacin status has the potential to influence every area of metabolism. Niacin deficiency has been linked to genomic instability largely through impaired function of the poly ADP-ribose polymerase (PARP) family of enzymes.
Matilda Florentin et al.
Current vascular pharmacology, 9(4), 385-400 (2011-02-15)
Treatment with statins has significantly reduced cardiovascular morbidity and mortality, an effect attributed to both the low-density lipoprotein cholesterol (LDL-C) lowering capacity and the pleiotropic actions of these drugs. However, residual risk remains even after intense LDL-C lowering. Therefore, additional
Janet E Digby et al.
Current opinion in lipidology, 20(4), 321-326 (2009-06-06)
Nicotinic acid is the most potent treatment clinically available for lowering LDL cholesterol and VLDL cholesterol and raising HDL cholesterol. The strong inverse relationship between coronary heart disease risk and HDL cholesterol at all levels of LDL cholesterol has, therefore
E T Bodor et al.
British journal of pharmacology, 153 Suppl 1, S68-S75 (2007-11-27)
Nicotinic acid has been used for decades to treat dyslipidaemic states. In particular its ability to raise the plasma HDL cholesterol concentration has led to an increased interest in its pharmacological potential. The clinical use of nicotinic acid is somewhat
查看所有相關論文

文章

HPLC Analysis of Water-Soluble B-Vitamins on Ascentis® Express C18

Pyridoxine hydrochloride, ≥98% (HPLC); Nicotinamide, ≥98.5% (HPLC); Thiamine hydrochloride, reagent grade, ≥99% (HPLC); Biotin, ≥99.0% (T); Folic acid, analytical standard; Cyanocobalamin (B12), analytical standard; Riboflavin (B2), analytical standard

HPLC Analysis of Water-Soluble B-Vitamins on Ascentis® Express C18

Pyridoxine hydrochloride, ≥98% (HPLC); Nicotinamide, ≥98.5% (HPLC); Thiamine hydrochloride, reagent grade, ≥99% (HPLC); Biotin, ≥99.0% (T); Folic acid, analytical standard; Cyanocobalamin (B12), analytical standard; Riboflavin (B2), analytical standard

條款

HPLC Analysis of Vitamins, Water Soluble on Discovery® C18

Separation of Pyridoxine; Nicotinamide; Nicotinic acid; Folic acid; (−)-Riboflavin, meets USP testing specifications; L-Ascorbic acid

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務